CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Price, Quote, News and Overview
NASDAQ:CNTA - Nasdaq - US1523091007 - ADR - Currency: USD
CNTA Quote, Performance and Key Statistics
CENTESSA PHARMACEUTICALS-ADR
NASDAQ:CNTA (1/31/2025, 8:22:07 PM)
After market: 16.92 0 (0%)16.92
+0.01 (+0.06%)
The current stock price of CNTA is 16.92 USD. In the past month the price increased by 1.01%. In the past year, price increased by 114.99%.
CNTA Latest News, Press Releases and Analysis
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission...
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
CNTA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.17 | 324.98B | ||
| AMGN | AMGEN INC | 14.85 | 153.42B | ||
| GILD | GILEAD SCIENCES INC | 21.94 | 121.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 905.25 | 118.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.81 | 73.95B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.99B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.67B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.98B | ||
| NTRA | NATERA INC | N/A | 23.36B | ||
| BIIB | BIOGEN INC | 8.81 | 20.97B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.86B |
Related stock screener links
About CNTA
Company Profile
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. The company is headquartered in Altrincham, Cheshire and currently employs 75 full-time employees. The company went IPO on 2021-05-28. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. The company is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
Company Info
CENTESSA PHARMACEUTICALS-ADR
3rd Floor, 1 Ashley Road
Altrincham CHESHIRE GB
CEO: Saurabh Saha
Employees: 72
Company Website: https://www.centessa.com/
Investor Relations: https://investors.centessa.com/
Phone: 447391789784
CNTA FAQ
What is the stock price of CNTA?
The current stock price of CNTA is 16.92 USD.
What is the symbol for CENTESSA PHARMACEUTICALS-ADR stock?
The exchange symbol of CENTESSA PHARMACEUTICALS-ADR is CNTA and it is listed on the Nasdaq exchange.
On which exchange is CNTA stock listed?
CNTA stock is listed on the Nasdaq exchange.
Is CNTA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for CNTA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of CNTA.
Does CNTA stock pay dividends?
CNTA does not pay a dividend.
What is the Price/Earnings (PE) ratio of CNTA?
CNTA does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).
What is the Short Interest ratio of CNTA stock?
The outstanding short interest for CNTA is 3.18% of its float.
CNTA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CNTA. When comparing the yearly performance of all stocks, CNTA is one of the better performing stocks in the market, outperforming 93.99% of all stocks.
CNTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNTA. The financial health of CNTA is average, but there are quite some concerns on its profitability.
CNTA Financial Highlights
Over the last trailing twelve months CNTA reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS increased by 6.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.45% | ||
| ROE | -54.83% | ||
| Debt/Equity | 0.27 |
CNTA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to CNTA. The Buy consensus is the average rating of analysts ratings from 14 analysts.